Every material Form 8-K Genprex, Inc. has filed with the SEC since October 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Genprex reported results from a translational analysis of whole-blood samples from 11 lung cancer patients treated with its lead drug candidate, REQORSA, presented as a poster at the Gerontological Society of America 2026 Annual Scientific Meeting. The company says the findings suggest a shift toward cellular repair and maintenance pathways, but the filing reports no revenue, earnings, guidance, or financing figures, so the news is exploratory and carries no reported financial impact.
Analysis used whole-blood samples from 11 lung cancer patients in two REQORSA clinical trials, taken before treatment and at 5 and 24 hours after infusion.
At 5 hours the response was dominated by innate immune pathways, which the company says is most consistent with a nonspecific reaction to the lipid nanoparticle delivery system.
At 24 hours the profile shifted toward cellular maintenance, and the poster was presented at the GSA meeting taking place November 4-7, 2026, in National Harbor, Maryland.
The filing includes forward-looking warnings and notes that the company's listing compliance on The Nasdaq Capital Market and its ability to continue as a going concern remain risk factors.
Genprex announced that preclinical and supportive clinical research identifies TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, REQORSA. The poster is scheduled for presentation at the 2026 EORTC-NCI-AACR Symposium in Barcelona, and the company says further research and prospective clinical evaluation are required before TROP2's predictive value is established.
Poster titled TROP2 Predicts Response to TUSC2 Gene Therapy is scheduled for Nov. 18, 2026 in Barcelona, Spain (Abstract 108, Board PB-108).
Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery.
The filing states the findings are preclinical with supportive clinical evidence and that additional research is needed to establish predictive utility.
The filing contains no financial results, guidance, or financing terms.
Genprex said research from its sponsored collaboration with Meharry Medical College will be featured at the Gerontological Society of America 2026 Annual Scientific Meeting, November 4-7, 2026. The work examines the TUSC2 gene, used in its lead oncology candidate REQORSA, in mitochondrial biology and aging-related processes. The company said further research is needed to determine whether the findings could support future therapeutic development.
Poster titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program" is scheduled for Wednesday, Nov. 4, 2026, 6:00-7:15 p.m. ET
Presenter is Mark S. Berger, MD, Chief Medical Officer of Genprex
Collaboration with Meharry Medical College was established in 2024
The filing does not state any financial terms or effects on the company's results
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Genprex, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →